DoD Gulf War Illness, New Investigator Award | W81XWH 20 GWIRP NIA

Opportunity Information: Apply for W81XWH 20 GWIRP NIA

The DoD Gulf War Illness Research Program (GWIRP) New Investigator Award (FY20; Funding Opportunity Number W81XWH-20-GWIRP-NIA) is a discretionary Department of Defense funding opportunity run through the U.S. Army Medical Research Acquisition Activity (USAMRAA) to bring new investigators into Gulf War Illness (GWI) research. The intent is to create a dedicated lane for researchers who do not yet have an established GWI program, so they can compete without being directly stacked against long-standing GWI laboratories. The mechanism supports work in the Discovery or Qualification phase, meaning projects should generate new ideas, early evidence, and proof-of-principle results that can be grown into larger studies later.

Eligibility is tied to the Principal Investigator meeting one of three defined career/experience categories: Transitioning Postdoctoral Fellow, Early-Career Investigator, or New GWI Researcher. Prior GWI experience is permitted but not required. When the PI has limited GWI background, the program strongly encourages meaningful collaboration with investigators who do have GWI experience and/or other specialized expertise needed for the question being asked. Applications are expected to explain what collaborators will contribute and how those partnerships strengthen the PI's ability to execute the project and interpret results.

The research scope is intentionally broad, allowing basic through clinical research, but the focus must remain on Gulf War Illness and on Veterans of the 1990-1991 Gulf War affected by GWI. Preliminary data are not required, which lowers the barrier to entry for new investigators and for novel concepts. Applicants may include preliminary data if they have it, and those data do not have to come specifically from GWI research. If no preliminary data are provided, the proposal is expected to rest on a solid scientific rationale, such as strong clinical observations or insights from other illnesses that share relevant symptom patterns with GWI.

A central review expectation is impact. Even if the project is early-stage and not expected to deliver an immediate treatment, the application must clearly lay out how results could ultimately lead to clinical impact for Veterans with GWI. In other words, the proposed work needs a believable line of sight to improved understanding, diagnostics, stratification, targets, or interventions that matter for patient outcomes, and the application must explicitly connect the project to features of GWI rather than treating it as a generic fatigue, pain, or neuroimmune condition.

For FY20, the GWIRP highlighted several emphasis areas where it had special interest (while still allowing applicants to propose other mission-relevant topics). These include identifying, replicating, and validating treatments that show promise for GWI, and identifying, replicating, and validating causes and treatment targets tied to dysregulated biological systems. The program calls out symptom domains and biological dysfunctions that frequently affect Veterans with GWI, including cognitive difficulties (memory deficits, mood, and behavior disturbances), sleep problems (non-restorative sleep and disturbances), chronic widespread pain, chronic debilitating fatigue, gastrointestinal issues (dietary intolerances, GERD, and functional GI disorders), sinus and respiratory effects, headaches, dermatological issues, neurological dysfunction (central, peripheral, autonomic, and/or neuromuscular), immune dysfunction, endocrine/exocrine/excretory dysfunction with particular attention to kidney and liver (including cytochrome P450 abnormalities), microbiome variants, the effect of stressors such as exertion or immune challenge on symptom severity and duration, and disordered crosstalk between systems (for example, immune changes altering the nervous system or autonomic dysfunction affecting GI function). Additional emphasis areas include identifying molecular signatures (genomic, proteomic, metabolic, epigenetic) that underlie symptoms and that can be used to group symptom sets by shared biology, as well as investigating comorbidities, mortality, and sex or ethnic differences.

The announcement also promotes participation in a dedicated GWI biorepository infrastructure called the Boston Biorepository, Recruitment, and Integrative Network (BBRAIN) for GWI. Applicants are encouraged to contribute biospecimens and data from Gulf War Veterans to this network to improve sharing and accelerate research across the field. This opportunity includes a nested Biorepository Contribution Option that can provide higher funding levels for projects that qualify and meet additional submission requirements.

Several activities are explicitly not supported. The program does not fund studies that frame psychiatric disease or psychological stress as the primary cause of GWI. It also does not support ALS-focused research; ALS can be included only if it is part of the study's GWI case definition and the focus remains on GWI symptomatology rather than ALS itself. Importantly, clinical trials are not allowed under this mechanism. The announcement uses the standard definition of a clinical trial as prospective assignment of human subjects to an intervention (including placebo or controls) to evaluate effects on health-related outcomes. Investigators wanting to run clinical trials are directed instead to other GWIRP mechanisms such as the Clinical Evaluation Award or Therapeutic/Biomarker Trial Award.

On funding and timing, the anticipated direct costs for the entire project period are capped at $500,000. The program expected to allocate roughly $800,000 total to fund about one award, meaning this is a highly competitive, limited-number opportunity. Awards were planned to be made no later than September 30, 2021, and projects funded with FY20 funds were subject to the availability window for those appropriations, with FY20 funds expiring for use on September 30, 2026. The opportunity was listed as open to unrestricted applicant organizations (subject to any additional eligibility clarifications in the full announcement), under CFDA 12.420, and it used grant and/or cooperative agreement instruments. The original closing date for submissions was September 10, 2020, with the opportunity first posted March 24, 2020.

• The Department of Defense, Dept. of the Army -- USAMRAA in the science and technology and other research and development sector is offering a public funding opportunity titled "DoD Gulf War Illness, New Investigator Award" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.420.
• This funding opportunity was created on Mar 24, 2020.
• Applicants must submit their applications by Sep 10, 2020. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• The number of recipients for this funding is limited to 1 candidate(s).
• Eligible applicants include: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled Additional Information on Eligibility.

Apply for W81XWH 20 GWIRP NIA

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: